FGF-1

FGF-1 (fibroblast growth factor 1; acidic FGF; aFGF) is an endogenous 155-amino-acid heparin-binding growth factor and the prototypic member of the 22-member FGF family, expressed in diverse tissues where it stimulates cell proliferation, survival, and migration through tyrosine kinase receptor (FGFR1-4) signaling, with particularly important roles in angiogenesis, wound healing, and tissue repair. FGF-1 activates FGFR to initiate MAPK/ERK, PI3K/Akt, and PLCgamma signaling cascades driving endothelial cell sprouting and neovascularization; in ischemic tissues, FGF-1 is a potent inducer of therapeutic angiogenesis, stimulating new vessel formation to restore perfusion in peripheral arterial disease and critical limb ischemia.

wound healing, hair growth support, skin repair, angiogenesis, fibroblast activation.

Research on FGF-1 primarily documents effects related to wound healing and hair growth support and skin repair and angiogenesis and fibroblast activation. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

For FGF-1, its FDA status is not evaluated by the FDA, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

In a double-blind phase 2 randomized controlled trial of 125 patients with critical limb ischemia and non-healing ulcers, intramuscular FGF-1 (NV1FGF plasmid gene therapy) significantly reduced the risk of all amputations (HR 0.498, p=0.015) and major amputations (HR 0.371, p=0.015) versus placebo, establishing the tissue repair and vascular regeneration properties of fibroblast growth factor-1 in ischemic wound healing.